Compare XERS & CERT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XERS | CERT |
|---|---|---|
| Founded | 2005 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Retail: Computer Software & Peripheral Equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.3B |
| IPO Year | 2018 | 2020 |
| Metric | XERS | CERT |
|---|---|---|
| Price | $6.72 | $9.57 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 9 |
| Target Price | $10.00 | ★ $14.50 |
| AVG Volume (30 Days) | ★ 2.8M | 2.8M |
| Earning Date | 11-06-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.07 |
| Revenue | $266,137,000.00 | ★ $415,551,000.00 |
| Revenue This Year | $43.89 | $11.70 |
| Revenue Next Year | $20.40 | $8.03 |
| P/E Ratio | ★ N/A | $142.07 |
| Revenue Growth | ★ 42.05 | 11.47 |
| 52 Week Low | $3.14 | $8.03 |
| 52 Week High | $10.08 | $15.69 |
| Indicator | XERS | CERT |
|---|---|---|
| Relative Strength Index (RSI) | 34.93 | 49.49 |
| Support Level | $6.47 | $8.75 |
| Resistance Level | $7.24 | $9.28 |
| Average True Range (ATR) | 0.29 | 0.36 |
| MACD | -0.02 | 0.23 |
| Stochastic Oscillator | 24.81 | 92.33 |
Xeris Biopharma Holdings Inc is a biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offer Recorlev for the treatment of Cushing's syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis (PPP).
Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval and increase patient access to medicines. The company has its business presence in the Americas which is also it key revenue generating market, EMEA and Asia Pacific region.